Diagnostic value of enhanced CT value in central lymph node metastasis of papillary thyroid carcinoma patients with Hashimoto’s thyroiditis
10.3760/cma.j.cn115807-20231018-00114
- VernacularTitle:增强CT值对桥本氏甲状腺炎合并甲状腺乳头状癌中央区淋巴结转移的诊断价值
- Author:
Ping DING
1
;
Tong ZHANG
;
Min TIAN
;
Peiying WEI
;
Zhijiang HAN
Author Information
1. 浙江中医药大学研究生院，杭州 310053
- Keywords:
Papillary thyroid cancer;
Hashimoto’s thyroid;
Central lymph node metastasis;
Computed tomography
- From:
Chinese Journal of Endocrine Surgery
2024;18(4):520-524
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the diagnostic efficacy of enhanced CT value in central lymph node metastasis (CLNM) of papillary thyroid carcinoma (PTC) with Hashimoto’s thyroiditis (HT) .Methods:The 209 central lymph nodes of 209 patients with PTC confirmed by surgery and pathology were retrospectively analyzed, and they were divided into HT group and non-HT group, including 77 lymph nodes (52 negative and 25 positive) in the HT-PTC group and 132 lymph nodes (74 negative and 58 positive) in the non-HT group. The CT values of lymph nodes were measured on enhanced CT images, and the optimal thresholds and corresponding sensitivity and specificity of enhanced CT values in the two groups were analyzed by the receiver operating characteristic curve.Results:The enhanced CT values of metastatic lymph nodes in the two groups were (103.2±21.1) Hu and (101.9±25.4) Hu, respectively ( t=0.23, P>0.05), and the enhanced CT values of benign lymph nodes were (72.0±15.8) Hu and (68.5±10.9) Hu, respectively ( t=-1.38, P>0.05). The area under the curve of enhanced CT values in the HT group and non-HT group were 0.882 and 0.918, respectively, and the optimal thresholds were 78.8 Hu and 74.7 Hu, respectively, with corresponding sensitivity of 92.0% and 91.4%, and specificity of 67.3% and 77.0%, respectively, for the diagnosis of CLNM in the two groups. Conclusion:The enhanced CT value has high and similar diagnostic efficiency for CLNM in HT group and non-HT group, providing a theoretical basis for the early clinical development of individualized treatment plans.
